Arcellx: Promising Up And Coming Player In The CAR-T Space

Aug. 24, 2022 9:52 AM ETArcellx, Inc. (ACLX)8 Comments


  • Arcellx shares have risen by 20% since February IPO and are up 131% over the past 3 months.
  • Arcellx's novel synthetic binding scaffold (D-Domain) is designed to overcome limitations of traditional CAR-Ts.
  • Data shared in June for CART-ddBCMA in r/r multiple myeloma showed promising response rate, quality of response and durability.
  • Management's strategy is to move quickly into a pivotal study in late-line patients as well as launch additional trials in earlier lines of therapy.
  • ACLX is a Buy for investors with long-term time frame. Key risks include further dilution in 2023 and fierce competition in multiple myeloma space as well as with BCMA-targeted therapies.
  • Looking for more investing ideas like this one? Get them exclusively at ROTY Biotech Community. Learn More »

Dendritic Cell activate T cells, trigger immune responses, they are responsible of cells protection of the body.

Design Cells

Shares of up-and-coming heme CAR-T player Arcellx (NASDAQ:ACLX) have risen by 20% since February IPO was priced at $15. After falling as far as the $6 level during Q2, the stock is up 131% over the past 3 months thanks to promising clinical

Weekly Chart



Corporate Slides

Superior Transduction

Corporate Slides

SparX Advantage

Corporate Slides

Comparison of response over time

Corporate Slides

Safety profile

Corporate Slides

Executive Compensation

10-K filing

Join 500+ investors and traders in the ROTY Biotech Community!

  • Participate in a Live Chat where members generously share due diligence, conviction picks and genuinely wish to see each other profit.
  • Get access to JF's high conviction ideas and quarterly updates on our model portfolios
  • Trade to Live, NOT Live to Trade philosophy (low maintenance, follow our thesis and make changes to positions only as merited)

Check out recent reviews of the service here.

This article was written by

Jonathan Faison profile picture
Community of Biotech Investors Focused on Value & Clinical Momentum

Founder of 500+ member ROTY Biotech Community (try the 2-week free trial to see if it adds value for you). Quality over quantity- enjoy connecting with readers.

Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: Disclaimer: Commentary presented is NOT individualized investment advice. Opinions offered here are NOT personalized recommendations. Readers are expected to do their own due diligence or consult an investment professional if needed prior to making trades. Strategies discussed should not be mistaken for recommendations, and past performance may not be indicative of future results. Although I do my best to present factual research, I do not in any way guarantee the accuracy of the information I post. I reserve the right to make investment decisions on behalf of myself and affiliates regarding any security without notification except where it is required by law. Keep in mind that any opinion or position disclosed on this platform is subject to change at any moment as the thesis evolves. Investing in common stock can result in partial or total loss of capital. In other words, readers are expected to form their own trading plan, do their own research and take responsibility for their own actions. If they are not able or willing to do so, better to buy index funds or find a thoroughly vetted fee-only financial advisor to handle your account.

Recommended For You

Comments (8)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.